EMA developing physician guidance for potential liver damage after taking Zolgensma
The European Medicines Agency is working on new advice for healthcare providers treating patients with Zolgensma, five months after two child patient deaths in Russia and Kazakhstan.
That includes monitoring the liver function of patients treated with the gene therapy and quickly assessing cases of suspected liver damage, Reuters first reported.
The EMA released its own statement after the Pharmacovigilance Risk Assessment Committee meeting on Jan. 12:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.